ORMP Oramed Pharmaceuticals Inc.

3.25
+0.01  (+0%)
Previous Close 3.24
Open 3.29
Price To Book 2.62
Market Cap 56,495,917
Shares 17,383,359
Volume 19,900
Short Ratio
Av. Daily Volume 48,915

NewsSee all news

  1. Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  2. Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

    NEW YORK, Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the

  3. Oramed to Present at Three Upcoming Conferences

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data due 4Q 2019.
ORMD-0801
Type 2 Diabetes
Phase 1 trial completed. Assessing options for future development.
ORMD-0901
Type 2 diabetes
Phase 2 first cohort to be completed 4Q 2019.
ORMD-0801
Non-alcoholic steatohepatitis (NASH)

Latest News

  1. Oramed to Present at Ladenburg Thalmann 2019 Healthcare Conference

    NEW YORK, Sept. 18, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems,

  2. Oramed Announces Last Patient Treated in Pivotal Phase IIb Trial of Oral Insulin ORMD-0801

    NEW YORK, Sept. 17, 2019 /PRNewswire/ --  Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced the

  3. Oramed to Present at Three Upcoming Conferences

    NEW YORK, Sept. 3, 2019 /PRNewswire/ -- Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today